The latest GHK-Cu news adds useful skin research, but it doesn't establish what injections do in people. FDA's ingredient review is still pending. Those are separate questions when a headline sounds like a treatment recommendation.
GHK-Cu is a peptide, a short chain of protein building blocks, attached to copper. As of September 30, 2026, the day this article was written, research has expanded while the FDA review remains pending.
Changelog
September 9, 2026 — a new way through skin. Sadeqi and colleagues, Advanced Healthcare Materials, tested STAR particles, tiny particles with needle-shaped tips. They increased delivery of copper tripeptide-1, another name for GHK-Cu, into pig skin kept in a laboratory. This measured delivery through skin, not a benefit or safety result in people.
August 29, 2026 — another review focuses on delivery. Najafi and colleagues, Archives of Internal Medicine Research, reviewed 64 records across several study models. They called for larger human trials of microneedle delivery, using tiny points to cross the skin surface. Those 64 records are not 64 patient trials.
August 27, 2026 — preparation details get closer scrutiny. A Pharmaceutics review by Mateescu and colleagues examined both the biology and the preparation's chemistry. Many studies did not establish how much copper stayed attached to the peptide or how much loose copper remained. A product's ingredient name alone cannot answer those questions.
August 20, 2026 — an evidence count puts the enthusiasm in context. Mokhtar and colleagues, Aesthetic Surgery Journal, found 20 eligible studies of cosmetic uses: 18 in cells or animals and two randomized human trials. Randomized means treatments were assigned by chance. Their search ended in March 2026, so the count doesn't include everything published afterward.
August 10, 2026 — a combination cream adds human data. Wang and colleagues, Skin Research and Technology, enrolled 32 adults; 30 completed 56 days. The cream contained 0.2% GHK-Cu and 5% ferment extract, material from bacterial cultures. Skin measurements changed during treatment, but everyone received the cream. Without a comparison group, the study cannot isolate GHK-Cu's contribution.
July 8, 2026 — wound materials advance in laboratory work. Xie and colleagues, Carbohydrate Polymers, published online a study of a hydrogel, a water-holding gel, containing GHK-Cu and other ingredients. They reported wound-repair findings in cell and animal experiments. The combined material was the treatment being tested; these were not patient results.
What the GHK-Cu news means for skin and hair
The practical change is a broader record of what has actually been tested. Different preparations, body areas and delivery methods still answer different questions. The GHK-Cu clinical evidence guide covers the earlier studies behind many familiar claims.
One earlier paper deserves attention because the August 27 review brings it into the discussion. A May 22, 2026 conference-proceedings study by Bo and colleagues tested a serum described as 2% GHK-Cu in 18 adults. Each person had one eyebrow assigned to the serum and the other to the same base without it.
The authors reported higher hair counts and thickness on the treated side at 12 weeks. That is small human eyebrow evidence. It doesn't establish a treatment for scalp hair loss, and it says nothing about injections. The review also noted that the study left the serum's precise chemical makeup unclear.
The broader guide to what GHK-Cu does explains the reasons scientists study it. Interest in a biological process and a measured benefit in patients remain different levels of evidence.
Blends need their own evidence
Glow combines GHK-Cu with BPC-157 and TB-500, two peptides studied around tissue repair. The current GHK-Cu papers don't establish how that complete blend behaves. A combination cream, a wound gel and a three-peptide blend each need evidence about their own contents and purpose.
The August chemistry review makes this distinction useful for a visit. Adding ingredients raises questions about whether they remain stable together and which ingredient accounts for a result. A finding about GHK-Cu alone cannot settle either question for Glow. A wider formula also makes an unwanted reaction harder to attribute to one component.
Where GHK-Cu's FDA review stands
The 503A bulks list concerns starting ingredients for medicines prepared for individual prescriptions under federal conditions. Category 1 means an ingredient is under evaluation; it is not the final list.
As of September 30, 2026, the day this article was written, FDA's current nominations PDF still reads “Updated May 14, 2026.” Its Category 1 entry says “GHK-Cu (except for injectable routes of administration).” That distinction separates use without injections from injected use.
FDA's safety page, current as of April 22, 2026, places injected GHK-Cu among withdrawn nominations. It retains concerns about possible unwanted responses from the body’s defenses to clumped peptide or impurities. Human safety data are limited. A nomination's withdrawal doesn't answer those safety questions.
Compounded GHK-Cu is a medication prepared for a prescription, different from an FDA-approved product. The formulation offered here is not FDA-approved. FDA explains that it does not check compounded medicines for safety, effectiveness or quality before they are marketed.
A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. The GHK-Cu regulatory history follows the spring nomination changes in detail.
What a provider considers now
A useful discussion starts with the problem being addressed and the outcome that would count as a meaningful change. The provider weighs the complete preparation, medical history, current medicines and supplements, and the evidence for that particular use.
Copper-handling disorders, liver problems, pregnancy or breastfeeding, and previous reactions belong in that history. The clinician also considers how follow-up will distinguish a treatment effect from ordinary variation or other changes in care. Trial concentrations are facts about tested products; they don't set an individual's prescription.
At Promise, a licensed provider reviews every request and not everyone qualifies. When treatment is prescribed, a licensed U.S. compounding pharmacy prepares the medication. That creates an accountable clinical relationship, while the research questions still need clinical trials to answer them.
What to watch next
As of September 30, 2026, the day this article was written, FDA's meeting page, still says before the end of February 2027. The page is marked “Content current as of: 04/15/2026”; the specific day and time remain unannounced. The Pharmacy Compounding Advisory Committee is an outside expert panel whose recommendations are advisory.
Human wound research is another development to follow. The CuHeal trial record, last updated February 27, 2026, lists recruiting status and planned enrollment of 60 adults, with no results posted. It compares topical GHK-Cu gel with the same gel base on paired small wounds. A posted study plan describes a question being tested; published results would provide an answer.
For the next human study, the useful details are the exact preparation, a fair comparison, enough people and time, and recorded unwanted effects. Those details would let a provider connect a result to the use being discussed. A larger eyebrow study would also help show whether the small May finding holds up.
